Sameek Roychowdhury is an Oncology physician. ClinicalTrials.gov lists 5 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
460 W 10th Ave
Columbus, OH 432101240
Telephone
614-293-6529Provider last certified this registry record 4 Dec 2020.
Clinical trials
- Infigratinib for the Treatment of Advanced or Metastatic Solid Tumors in Patients With FGFR Gene Mutations
Sponsor: Sameek Roychowdhury
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
6 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Partner Therapeutics, Inc.Program year20254 payments
- TAIHO ONCOLOGY, INC.Program year20242 payments
- AstraZeneca Pharmaceuticals LPProgram year20241 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
43.9%Other antidepressants16.7%Mirtazapine100%Part D<11 patientsSSRI15.2%Citalopram Hbr100%Part D<11 patients+ 1 more class in this area
Cancer & immunology
29.5%Kinase inhibitor29.5%Imatinib Mesylate33%Lapatinib33%Pemazyre33%Part D<11 patientsAnti-infectives
9.1%Cephalosporin Antibacterial9.1%Cefdinir100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
7 NIH research awards on record, funded 2016–2026 per NIH RePORTER. The latest:
- Clinical validation of FGFR-Dx in plasma cell-free DNA from patients with FGFR-altered advanced pancreatic cancer
Ohio State University
FY2026$327,020UH3CA313817 - Liquid Biopsy for Rapid Detection and Real Time Monitoring of FGFR-altered Cancers
Ohio State University
FY2025$326,741UH3CA262220 - Liquid Biopsy for Rapid Detection and Real Time Monitoring of FGFR-altered Cancers
Ohio State University
FY2024$310,411UH3CA262220
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Freddie Bray
Centre National de la Recherche Scientifique
Jacques Ferlay
Centre international de recherche sur le cancer
Hermann Brenner
German Cancer Research Center
Isabelle Soerjomataram
Centre international de recherche sur le cancer
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”